Takeda Pharmaceutical Books Second-Quarter Net Loss on Impairment of Certain Products
By Kosaku Narioka
Takeda Pharmaceutical reported a second-quarter net loss due to impairment losses on certain products and cut its net-profit forecast for the fiscal year ending March 2024.
The Japanese drugmaker said Thursday that it booked a net loss of 48.0 billion yen ($319.5 million) for the three months ended Sept. 30. That compared with the estimated net profit of Y70.41 billion in a poll of analysts by Quick and net profit of Y61.7 billion in the year-earlier period.
Takeda now projects that its net profit for the fiscal year ending March 2024 will drop 71% to Y93.00 billion, compared with its previous view of a 55% fall to Y142.00 billion.
Second-quarter revenue increased 6.4% from a year earlier to Y2.102 trillion. Sales of Vyvanse, a drug for attention deficit hyperactivity disorder, fell 7.3% to Y103.1 billion as Takeda lost U.S. market exclusivity for the drug in late August.
Write to Kosaku Narioka at kosaku.narioka@wsj.com
(END) Dow Jones Newswires
October 26, 2023 03:14 ET (07:14 GMT)
Copyright (c) 2023 Dow Jones & Company, Inc.-
5 Undervalued Energy Stocks to Play the AI Data Center Demand Boom
-
After Earnings, Is Lowe’s Stock a Buy, Sell, or Fairly Valued?
-
5 Stocks With the Largest Fair Value Estimate Cuts After Q1 Earnings
-
10 Stocks With the Largest Fair Value Estimate Increases After Q1 Earnings
-
Markets Brief: Inflation Back in the Spotlight
-
AI Is Booming, but Consumer Spending Is Slowing. Which Will Prevail in the Stock Market?
-
What’s Happening In the Markets This Week
-
Is the Era of Volatility-Suppressing Policies Possibly Over?
-
After Earnings, Is Nvidia Stock a Buy, Sell, or Fairly Valued?
-
The 10 Best Companies to Invest in Now
-
Salesforce Earnings: Slowing Growth and Risk of More Disappointment Ahead
-
Chewy Earnings: Market Likes Repurchase Program and Profit Improvements
-
This 5-Star Stock With a Dividend Yield That Tops 4% Is a Buy
-
After Earnings, Is Target Stock a Buy, Sell, or Fairly Valued?
-
Obesity Drug Stocks: Where to Invest Now
-
How to Invest Like Warren Buffett